Mr. Pratap Sandhu reports

THE PRECISION PEPTIDE COMPANY APPLAUDS FDA ADVISORY COMMITTEE VOTE ON EXPANDED PATHWAY FOR BPC-157 AND KPV

The Precision Peptide Company Inc. applauds today's vote by the U.S. Food and Drug Administration's (FDA) pharmacy compounding advisory committee, which recommended that BPC-157 and KPV (lysine-proline-valine) be considered for inclusion on the FDA's 503A bulks list. While the recommendation is advisory and subject to final FDA review, the company believes it represents a positive step toward improving patient access to quality-focused, professionally compounded peptide therapies.

If ultimately adopted by the FDA, today's advisory committee recommendation represents a significant step toward allowing U.S. patients to legally access physician-prescribed BPC-157 through regulated compounding pharmacies, replacing much of the current reliance on unregulated sources.

KPV, like BPC-157, has received a favourable FDA advisory committee recommendation for inclusion on the 503A bulks list and is now advancing through the FDA's regulatory process. It has not yet received FDA approval or final list inclusion.

This comes shortly after the company's news release dated July 14, 2026, highlighting that the company received a 20,000-unit production run of its BPC-157 transdermal patch. The patches are manufactured and independently tested in the United States and mark the company's transition from testing to commercialization. Each patch is formulated to deliver two milligrams of BPC-157, consistent with the third party test results, which confirmed 95.5-per-cent chromatographic purity, exceeding the greater-than-or-equal-to-95-per-cent threshold that is widely recognized across the peptide industry as the analytical benchmark for high-purity grade peptide products, and a quantified dose of 2.02 milligrams of BPC-157 per patch.

The committee's decision reflects the growing recognition that patients and health care providers are seeking regulated, pharmacy-compounded alternatives to an unregulated grey market. By supporting a more structured regulatory pathway, the FDA has the opportunity to enhance patient safety, quality standards and oversight while encouraging continued scientific and clinical evaluation of peptides such as BPC-157 and KPV.

"The committee's vote is an encouraging development for patients, health care practitioners, and the broader peptide industry," said Pratap Sandhu, chief executive officer of The Precision Peptide Company. "We believe patients are best served when innovative therapies are produced through licensed pharmacies operating under established regulatory frameworks rather than through unregulated channels. This recommendation is a step toward improving quality, transparency and patient safety."

The Precision Peptide Company remains committed to developing pharmaceutical-grade peptide products through rigorous manufacturing, quality assurance and evidence-based innovation. As the regulatory landscape continues to evolve, the company looks forward to supporting responsible commercialization efforts that prioritize patient safety, physician oversight and product quality.

About The Precision Peptide Company Inc.

The Precision Peptide Company is focused on developing premium peptide-based health and wellness products with an emphasis on scientific integrity, pharmaceutical-quality manufacturing and innovative delivery technologies. The company is committed to advancing responsible access to peptide therapies through research, education and regulatory compliance.

Select corporate milestones to date:

• Dual listed on the Canadian Securities Exchange (symbol: BPC) and the OTCQB (symbol: PNGAF);
• Commercialized a portfolio of peptide-based wellness products spanning recovery, cognitive, longevity, gut-health, dermal, hair and skin categories;
• Advancing a proprietary transdermal microneedle delivery platform and consumer patch line designed to deliver peptides without injections or cold-chain storage.

We seek Safe Harbor.